September 11, 2009
New Data from CLARITY Study on Disease Activity in MS Patients
Who Received Cladribine Tablets Presented at 25th ECTRIMS Congress
· Post-hoc analysis from CLARITY study show that short-course oral treatment with Cladribine Tablets significantly increased the proportion of patients who had absence of disease activity compared with placebo
Düsseldorf, Germany, and Geneva, Switzerland,
September 11, 2009 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced new data from a post-hoc analysis of the two-year (96-week) placebo-controlled CLARITY1 Phase III trial using a short-course of Cladribine Tablets (Merck Serono’s proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS). The data from this post-hoc analysis of the CLARITY study were presented at the 25th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.2
New Data from CLARITY Study on Disease Activity in MS Patients
Who Received Cladribine Tablets Presented at 25th ECTRIMS Congress
· Post-hoc analysis from CLARITY study show that short-course oral treatment with Cladribine Tablets significantly increased the proportion of patients who had absence of disease activity compared with placebo
Düsseldorf, Germany, and Geneva, Switzerland,
September 11, 2009 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced new data from a post-hoc analysis of the two-year (96-week) placebo-controlled CLARITY1 Phase III trial using a short-course of Cladribine Tablets (Merck Serono’s proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS). The data from this post-hoc analysis of the CLARITY study were presented at the 25th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.2
0 comments:
Post a Comment